Autoimmune Disease Diagnoses Quietly Shape Patients’ Decisions About Having Children

For people living with autoimmune connective tissue diseases, the question of whether to have children is rarely a simple one. These chronic conditions, which include lupus, dermatomyositis, and related disorders, attack the body’s own tissues and demand long-term treatment with medications that can carry serious risks during pregnancy. A new cross-sectional survey study published in the Archives of Dermatological Research by researchers at the University of Nebraska Medical Center and the University of Utah has turned a careful eye on this deeply personal intersection of medicine and life planning, asking how diagnoses and their treatments actually influence patients’ reproductive decisions.

The research team, led by Sophie Gart and corresponding author Sarah Lonowski, designed a survey to capture what patients with autoimmune connective tissue diseases experience when weighing pregnancy and family building against the realities of their illness. The study was reviewed and deemed exempt by the University of Nebraska Institutional Review Board, and the authors report no competing interests. Their work arrives at a moment when clinicians increasingly recognize that reproductive counseling for patients with rheumatologic and dermatologic disease cannot be an afterthought, but must be woven into routine care from the moment of diagnosis.

Autoimmune connective tissue diseases disproportionately affect women, and they often strike during the reproductive years, precisely when many patients are considering whether and when to start a family. Systemic lupus erythematosus, one of the most studied of these conditions, is associated with elevated risks of preeclampsia, preterm birth, and pregnancy loss, particularly when the disease is active at the time of conception. Other connective tissue disorders carry their own obstetric complications, and the medications used to control them add another layer of complexity, since some immunosuppressive agents are considered compatible with pregnancy while others are clearly contraindicated because of teratogenic potential.

This biological and pharmacological landscape forms the backdrop against which patients make reproductive choices. Prior literature has documented that many patients with rheumatic diseases receive little or no formal counseling about contraception, fertility preservation, or pregnancy planning, leaving them to piece together information from fragmented sources. A qualitative study published in BMJ Open in 2025 examined the sexual and reproductive health perspectives of patients with autoimmune rheumatic diseases in Mexico and found substantial unmet needs in this domain, underscoring that the problem crosses borders and health systems. The new survey study extends this line of inquiry by systematically assessing how diagnoses and treatments shape reproductive decision-making in a cross-sectional cohort.

The methodological approach of a cross-sectional survey is well suited to capturing a snapshot of patient attitudes and experiences at a single point in time. Participants are asked about their disease diagnoses, the treatments they receive, and the ways these factors have entered into their thinking about having children. By linking disease characteristics and medication exposure to reported reproductive intentions and concerns, the study design allows researchers to identify patterns that might otherwise remain invisible in clinical encounters, where the pressures of managing active disease often crowd out conversations about family planning.

The pharmacological dimension of this question is particularly intricate. Dermatologic and rheumatologic medications span a wide spectrum of pregnancy safety, and recent comprehensive reviews, including a 2024 update in the Journal of the American Academy of Dermatology on the safety of dermatologic medications in pregnancy and lactation, have worked to consolidate the evidence. Some drugs, such as certain antimalarials and azathioprine, are generally regarded as acceptable during pregnancy under specialist supervision, while others, including methotrexate and mycophenolate mofetil, require strict avoidance and reliable contraception because of documented fetal harm. Patients who take these medications face a genuine dilemma: discontinuing effective therapy to attempt pregnancy can trigger disease flares that themselves endanger both mother and fetus, while continuing treatment may foreclose the possibility of carrying a pregnancy safely.

Earlier work in the rheumatology literature has emphasized that fertility preservation and the maintenance of reproductive potential should be explicit goals when managing patients with rheumatic diseases who need anti-inflammatory and immunosuppressive drugs. A 2010 review in Arthritis Care and Research argued that protecting fertility should be part of treatment planning rather than an afterthought, a principle that has gradually gained traction but remains unevenly implemented in practice. The new survey study speaks directly to this gap by documenting, from the patient’s own perspective, how the burden of diagnosis and treatment translates into hesitation, delay, or outright abandonment of reproductive goals.

The epidemiology of connective tissue disorders helps explain why this issue deserves broad attention. As reviewed in the journal Rheumatology, these conditions collectively affect a substantial share of the population, and because they preferentially arise in women of childbearing age, the number of patients confronting reproductive decisions in the context of chronic autoimmune disease is far from trivial. Each of these patients represents an individual navigating uncertainty about disease activity, medication safety, genetic risk, and the physical demands of pregnancy on a body already under immunological assault. The cumulative effect, as the survey data suggest, is that reproductive planning becomes an area of significant anxiety and often of inadequate clinical support.

What makes the Nebraska and Utah study notable is its focus on the patient’s voice. Rather than inferring reproductive concerns from clinical records or proxy measures, the researchers asked patients directly about how their diagnoses and treatments affected their decisions. This approach acknowledges that reproductive decision-making is not purely a medical calculation; it is shaped by fear of disease transmission to offspring, by the experience of fatigue and pain, by the practical challenges of parenting with a chronic illness, and by the trust or distrust patients feel toward the medications they depend on. A survey instrument designed by clinicians who care for these patients, as the authors report, can surface these considerations in a structured way that informs both research and practice.

The implications of the study reach into several corners of clinical medicine. Dermatologists, rheumatologists, obstetricians, and primary care physicians all share responsibility for patients with autoimmune connective tissue diseases, and the findings argue for earlier, more proactive reproductive counseling that begins at diagnosis rather than when a patient announces a pregnancy. Preconception planning, in which medications are reviewed and adjusted, disease activity is optimized, and pregnancy risks are quantified, has been shown in related conditions to improve maternal and fetal outcomes. The survey evidence suggests that many patients are making decisions without the benefit of such coordinated planning, and that addressing this shortfall could meaningfully change the reproductive trajectories of people living with chronic autoimmune disease.

As the scientific community continues to refine its understanding of pregnancy safety in immunosuppressive therapy, studies like this one serve as a reminder that the ultimate measure of clinical progress is not only disease control but the preservation of patients’ full life goals, including the choice to become parents. The research letter by Gart, Griffin, Lyden, and Lonowski adds a carefully gathered body of patient-reported evidence to a field that has long needed it, and it points toward a model of care in which reproductive health is treated not as a separate concern but as an integral part of managing autoimmune connective tissue disease from the very first appointment.

Subject of Research: The influence of autoimmune connective tissue disease diagnoses and treatments on patients' reproductive decision-making

Article Title: Assessing how autoimmune connective tissue disease diagnoses and their treatments affect patients’ reproductive decisions: a cross-sectional survey study

Article References: Gart, S., Griffin, J., Lyden, E., & Lonowski, S. (2026). Assessing how autoimmune connective tissue disease diagnoses and their treatments affect patients’ reproductive decisions: a cross-sectional survey study. Archives of Dermatological Research, 318(1), Article 507. https://doi.org/10.1007/s00403-026-04999-5

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04999-5

Keywords: autoimmune connective tissue disease, systemic lupus erythematosus, reproductive decisions, pregnancy, immunosuppressive medications, fertility, cross-sectional survey, dermatology, rheumatology, preconception counseling, medication safety, family planning